Schrodinger IncSchrödinger's software and services are central to the quantum and AI drug discovery trend, with its leadership in molecular simulation driving demand.
Quantum computing and artificial intelligence are breaking down barriers in the global pharmaceutical industry. By simulating molecules at the subatomic level on computers, they slash drug discovery timelines from an average of 10 to 15 years down to just months, saving tens of billions of dollars in costs. Major pharmaceutical companies are turning to advanced computing power through platforms from infrastructure providers like Schrödinger and NVIDIA, two key case studies that dominate this infrastructure. Schrödinger is a leader in molecular physics simulation software, developed over 30 years, generating revenue from both SaaS software and drug discovery services. Meanwhile, NVIDIA has launched BioNeMo, a cloud-based generative AI platform specifically for drug development, locking in the ecosystem from GPU hardware to enterprise software. Investing in this theme means investing in the platforms and software that global drug companies must use, reducing the traditional risks of biotech stocks and aligning with major global trends through a safer risk structure.
Schrodinger IncSchrödinger's software and services are central to the quantum and AI drug discovery trend, with its leadership in molecular simulation driving demand.
NVIDIA CorporationNVIDIA's BioNeMo platform is highlighted as a key infrastructure for AI-driven drug discovery, indicating strong demand for its products.